CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03753919
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:14.297739+00:00
Published At: 2026-03-11T00:00:00+00:00
Record Updated At: 2026-03-11
Results Posted At: 2026-03-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Thyroid Papillary Carcinoma", "Metastatic Thyroid Follicular Carcinoma", "Metastatic Thyroid Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-11"
protocolSection.identificationModule.nctId: "NCT03753919"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-03-11"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.